Figure 2.

Time course of glycated hemoglobin (HbA1c) in Japanese patients with type 2 diabetes mellitus treated with double‐blind sitagliptin 50 mg/day or the placebo added to voglibose for the first 12 weeks and open‐label sitagliptin 50 or 100 mg/d added to voglibose for the subsequent 40 weeks. The data are values for mean ± standard error (SE), and results from the patients who received the placebo during the double‐blind period and open‐label sitagliptin in the open‐label period (P/S group) and patients who received sitagliptin in both periods (S/S group) treatment groups are shown with open and closed circles, respectively. Statistics for HbA1c were calculated using at each time‐point the data available for that specific time‐point. The sample sizes at each time‐point are shown beneath the plots.